MeRes100 BRS - the World's First Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold - Shows Consistent Long-term Positive Safety With Consistent Low MACE rates and Zero Scaffold Stent Thrombosis for Patients With Coronary Artery Disease

LONDON, July 11, 2019 /PRNewswire/ -- Meril's recently CE-approved MeRes100, used for the treatment of de-novo coronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rate of 1.87% at three years as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years.

"First generation bioresorbable scaffolds have not shown the most favourable results at long term. MeRes100, a next generation bioresorbable scaffold, has been developed with reduced strut thickness, an improved profile for better deliverability, faster degradation and possibly lower scaffold thrombosis," said principal investigator for the MeRes-1 trial Dr Ashok Seth, Chairman of Fortis Escorts Heart Institute in New Delhi, India. 

MeRes-1 

Long-term three-year follow-up data of the MeRes-1 first in-human study, published in EuroIntervention¹, demonstrated the high efficacy of MeRes100 BRS with multimodality imaging at two years including:

• Low late lumen loss (0.24±0.34mm) with quantitative coronary angiography (QCA)
• Virtually complete strut coverage (99.24%) with optical coherence tomography (OCT)
• Sustained mean flow area and very low percentage volume obstruction (7.5%) with intravascular ultrasound (IVUS)

MeRes-1 Extend

Two-year data from this global study, which enrolled patients from Brazil, Europe and Asia, demonstrated relatively low late lumen loss (0.18±0.31mm) with a serial QCA analysis at six-month follow-up suggesting high efficacy on inhibiting NIH at late follow-up, and a sustained mean flow area and virtually complete strut coverage (97.9±3.7) shown in an OCT subset analysis at six months.²

"The encouraging results from MeRes100 BRS are changing the way we currently view bioresorbable scaffolds," said Dr Ashok Thakkar, Head Clinical Research at Meril Life Sciences. "We are aiming to continue further developing the clinical evidence of this next generation technology against a drug-eluting stent in a randomised setting in due course."   

About MeRes100 BRS
MeRes100 BRS? a product indigenously designed and manufactured in India by Meril Life Sciences, is a bioresorbable vascular scaffold system with low strut thickness of 100microns that fully resorbs naturally in the artery within a period of 2-3 years thus leaving the vessel in its true form and nature.

About Meril
Founded in 2006, Meril is a global medical device company dedicated to innovate, design & develop novel, clinically relevant and state-of-the-art vascular intervention devices, Orthopaedic implants, in-vitro diagnostics, endo-surgery and ENT products. For more information about Meril, please visit https://www.merillife.com/. Follow Meril Life Sciences on LinkedIn here.

References
1. Ashok S, et al. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. EuroIntervention. 2019;15:1?9   
2. Abizaid A. MeRes-1 Extend study: Imaging and two-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. Presented at EuroPCR 2019

European media enquiries:

Daniel Bullock
Four Health Communications, London
T: +44-(0)20-3761-4485
E: [email protected]

SOURCE Meril Life Sciences